Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry

Blanca Espinet1,2, Ana Ferrer1,2, Beatriz Bellosillo1,2, Lara Nonell3, Antonio Salar2,4, Concepción Fernández-Rodríguez2, Eulàlia Puigdecarnet3, Javier Gimeno1, Mar García-García1,2, Maria Carmen Vela1, Elisa Luño5, Rosa Collado6, José Tomás Navarro7, Esmeralda de la Banda8, Pau Abrisqueta9, Leonor Arenillas1,2, Cristina Serrano10, Josep Lloreta1,2, Belén Miñana11, Andrea Cerutti12, Lourdes Florensa1,2, Alberto Orfao13, Ferran Sanz14, Francesc Solé1,2, David Domínguez-Sola15* and Sergio Serrano1*

1Servei de Patologia, Hospital del Mar, Barcelona; 2Programa de Recerca en Càncer, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona; 3Servei d’Anàlisi de Microarrays, IMIM, Barcelona; 4Servei d’Hematologia, Hospital del Mar, Barcelona; 5Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo; 6Servicio de Hematología, Hospital General Universitario de Valencia, Valencia; 7Servei d’Hematologia, ICO-Hospital Germans Trias i Pujol, Barcelona; 8Servei d’Hematologia, IDIBELL-Hospital de Bellvitge, L’Hospitalet de Llobregat; 9Servei d’Hematologia, Hospital Universitari Vall d’Hebron, Barcelona; 10Laboratorio de Citometría de Flujo, Servicio de Hematología, Fundación Jiménez Díaz, Madrid; 11Centre de Regulació Genòmica, Barcelona; 12Institut Català de Recerca i Estudis Avançats (ICREA), IMIM, PRBB, Barcelona; 13Servicio General de Citometría, Centro de Investigación del Cáncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Salamanca; 14Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra,
PRBB, Barcelona; Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.

*These authors contributed equally to this work.

Running title: Asymptomatic monoclonal cyclin D1-positive B-cell lymphocytosis

Key Words (5)
Asymptomatic monoclonal cyclin D1-positive lymphocytosis, non-nodal indolent mantle cell lymphoma, gene expression profiling, CD38/CD200, flow cytometry.

Corresponding Author
David Dominguez-Sola, MD, PhD
Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. Phone: +1-212-851-5270, Fax: +1-212-851-5256, e-mail: dd2115@columbia.edu

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Word count: 5349
Tables: 1
Figures: 5
Supplementary Tables: 6
Supplementary Figures: 3
Translational relevance

This manuscript shows for the first time that monoclonal asymptomatic lymphocytosis, cyclin D1-positive (MALD1), in contrast to typical mantle cell lymphoma (MCL), is characterized by immune activation and is driven by inflammatory cues. This distinct biology translates into a benign clinical course. It also shows that assessment of CD38 and CD200 by flow cytometry is useful to distinguish most cases of MALD1 from MCL in the clinical setting. According to these results, most of the MALD1 cases can be clearly identified and segregated from the current MCL category avoiding overdiagnosis and unnecessary treatment.
Abstract

Purpose: According to current diagnostic criteria, mantle cell lymphoma (MCL) encompasses the usual, aggressive variants and rare, non-nodal cases with monoclonal asymptomatic lymphocytosis, cyclin D1-positive (MALD1). We aimed to understand the biology behind this clinical heterogeneity and to identify markers for adequate identification of MALD1 cases.

Experimental Design: We compared 17 typical MCL cases with a homogeneous group of 13 untreated MALD1 cases (median follow-up, 71 months). We performed gene expression profiling with functional analysis in 5 MCL and 5 MALD1. Results were validated in 12 MCL and 8 MALD1 additional cases by qRT-PCR and in 24 MCL and 13 MALD1 cases by flow cytometry. Classification and regression trees strategy was used to generate an algorithm based on CD38 and CD200 expression by flow cytometry.

Results: We found 171 differentially expressed genes with enrichment of neoplastic behavior and cell proliferation signatures in MCL. Conversely, MALD1 was enriched in gene sets related to immune activation and inflammatory responses. CD38 and CD200 were differentially expressed between MCL and MALD1, and confirmed by flow cytometry (median CD38, 89% vs. 14%; median CD200, 0% vs. 24%, respectively). Assessment of both proteins allowed classifying 85% (11/13) of MALD1 cases, while 15% remained unclassified. SOX11 expression by qRT-PCR was significantly different between MCL and MALD1 groups but did not improve the classification.

Conclusion: We show for the first time that MALD1, in contrast to MCL, is characterized by immune activation and driven by inflammatory cues. Assessment of CD38/CD200 by flow cytometry is useful to distinguish most cases of MALD1 from MCL in the clinical setting. MALD1 should be identified and segregated from the current MCL category to avoid overdiagnosis and unnecessary treatment.

Abstract word count: 276
Introduction

Mantle cell lymphoma (MCL) is a lymphoproliferative disorder of mature B-cells genetically characterized by the presence of t(11;14)(q13;q32), that juxtaposes the CCND1 proto-oncogene, encoding for cyclin D1 at chromosome 11q13, to the immunoglobulin heavy chain gene, at chromosome 14q32. As a consequence, deregulated expression of the cyclin D1 protein occurs in the mature B-cell compartment (1). While t(11;14)(q13;q32) is considered a primary event in the pathophysiology of MCL, at least in part by deregulating cell cycle progression in the target cells (2), this chromosome translocation does not seem to be sufficient for the full transformation of B-cells. Different experimental and clinical observations suggest that additional oncogenic events are required for the development of MCL (3, 4).

Patients with MCL have a poor prognosis with a median overall survival between 3 and 5 years (5). However, cases that meet the WHO classification diagnostic criteria for MCL, but lack its aggressive clinical course, have been reported and dubbed as indolent forms of MCL. Such cases are typically characterized by leukemic involvement, with or without splenomegaly and absence of lymphadenopathies, for which they have also been referred to as non-nodal MCL (6-13). In the last years, we and others have proposed that some of these asymptomatic cases may represent a preneoplastic condition that could lead to the development of MCL or instead correspond to other types of lymphoproliferative disorders with the t(11;14)(q13;q32) (8, 13-15).

In an attempt to gain further insight into the heterogeneous behavior of MCL, we have compared a series of classical MCL cases requiring chemotherapy with a homogeneous group of asymptomatic individuals harboring a monoclonal expansion of cyclin D1-positive mature B-cells in the peripheral blood (PB), that carry the t(11;14)(q13;q32), in the absence of splenomegaly or nodal enlargement due to this
process. These cases will be hereafter referred to as MALD1 (monoclonal asymptomatic lymphocytosis, cyclin D1-positive), with the intention of not to prejudge the neoplastic nature of the process. Of note, these asymptomatic cases has ever required or received any treatment after a minimum follow-up of 26 months (median, 71 months). In this study, we have sought for biological differences between MALD1 and classical MCL, investigating molecular pathways that could be enriched in each of these groups. Finally, we selected differentially expressed genes whose protein products could be easily analyzed by flow cytometry, to develop a useful tool for distinguishing MALD1 from classical MCL in routine clinical practice.
Materials and Methods

Patients and samples

Thirty patients studied between 1994 and 2012 who fulfilled the WHO diagnostic criteria for MCL and had available cryopreserved PB samples were included in this study (1). From them, 17 were diagnosed with MCL requiring chemotherapy at diagnosis, and 13 corresponded to individuals with monoclonal expansion of mature B-cells in PB carrying the t(11;14)(q13;q32) and displaying cyclin D1 overexpression (MALD1). Aggressive variants with blastoid or pleomorphic features were excluded from the MCL group. Criteria for inclusion in the MALD1 group were as follows: lack of symptoms, no enlargement of lymphoid organs related to the process (by physical examination or by imaging studies), and follow-up > 2 years without requiring any treatment along the whole follow-up period. The decision not to treat was based on a number of features including lack of constitutional symptoms, absence of progressive or bulky disease and no severe cytopenia or impaired end-organ function as a consequence of the process. In this setting, a watchful waiting approach was adopted. Eight healthy individuals with similar age and gender distribution were also included as controls for microarray analyses. This study was approved by the Institutional Review Board of the participating institutions, where required, and was conducted in accordance with the Declaration of Helsinki.

Histological, immunohistochemical and immunocytochemical studies

Histological and immunohistochemical analyses were performed on formalin-fixed, paraffin-embedded (FFPE) samples. Immunocytochemical studies were carried out on air-dried formalin-acetone fixed PB smears. Cyclin D1 expression was assessed on histological sections and/or PB smears of all cases with t(11;14), regardless of CD5 expression. In each case, two primary antibodies were used: clone P2D11F11
(Novocastra, NewCastle, UK) and clone SP4 (Neomarkers Inc, Fremont, CA, USA). The immunohistochemical analysis of SOX11 was performed with an anti-SOX11 polyclonal antibody (Atlas Antibodies, Stockholm, Sweden), as previously described (9). SOX11 immunostaining on decalcified tissues is not sensitive enough so it was not performed in BM biopsies. The percentage of Ki-67 positive cells (clone MIB-1, Dako, Glostrup, Denmark) was recorded for all available cases.

*Morphologic and immunophenotypic analysis of B-lymphocytes*

PB and bone marrow (BM) smears were stained with May-Grünwald-Giemsa. CD38 and CD200 expression was analyzed in PB by flow cytometry using a mouse IgG1 anti-human CD38 moAb (HB7, BD Biosciences, San Jose, CA, USA) and a mouse IgG1 anti-human CD200 moAb (MRCOX-104, BD Biosciences). The expression of both markers was assessed with respect to the mean fluorescence intensity observed in cells labelled with a matched isotypic monoclonal antibody. Lymphocytes were gated in the forward and side scatter plot to avoid the inclusion of debris, monocytes, and doublets. Regarding CD200 expression analysis, and in order to ensure the exclusion of possible contaminating T and natural killer cells, the resultant cells were then gated to select CD2+ cells, which were electronically excluded (invert gate).

*G-banding cytogenetics and fluorescence in situ hybridization (FISH)*

Chromosome analyses were carried out on lymphoid cells from PB and BM 72-hour TPA-stimulated cultures following standard procedures (16). When karyotypes presented with three or more cytogenetic aberrations, these were classified as complex. FISH analysis was performed on PB and BM using the *IGH/CCND1* dual color dual fusion translocation probe and *ATM* and *TP53* locus specific probes (Abbott Molecular, Abbott...
Park, IL, USA). Cut-offs were 1%, 10% and 10%, respectively. FISH for *IGH/CCND1* was also performed on FFPE samples (cut-off 15%) (17).

**Analysis of the major translocation cluster (MTC) breakpoint region of *IGH/CCND1* and cyclin D1 mRNA isoforms**

Analysis of the MTC breakpoint region of *IGH/CCND1* was performed following the BIOMED-2 protocol (18). Positive cases were sequenced by capillary electrophoresis. Sequences were aligned to previously reported MTC region sequences using ClustalW. Identification of the *IGHJ* segments involved in the translocation and alignment to previously reported sequences were performed using the IgBlast public server. *CCND1* mRNA isoforms were assessed as previously described (19).

**Mutational studies of immunoglobulin heavy chain V (IGHV) genes**

The mutational status of *IGHV* genes was assessed as previously described (20). Samples in which < 2% of base pairs differed from those of the consensus sequence were considered unmutated.

**Microarray analyses**

Microarray analyses were performed on RNA isolated from B-lymphocytes obtained from PB by means of immunomagnetic bead selection (B-cell isolation kit II, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) that yielded purities of ≥90% as assessed by flow cytometry (CD19 APC, clone SJ25C1, BD Biosciences). In cases carrying the t(11;14)(q13;q32) translocation, the percentage of pathologic cells as assessed by flow cytometry was ≥ 80% of total B-lymphocytes.

Microarray expression profiles were obtained using the Affymetrix Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA). Raw data were normalized to a
logarithmic transcript-level using the robust multi-chip average (RMA) (21) and core annotations, obtaining a total of 18,708 transcript clusters. Normalized data were then filtered to avoid noise created by non-expressed transcript clusters. This filtering was performed in two steps: first, only transcripts with intensity signal > 10% of the mean of all intensities of the studied groups were selected; then, those with a variance > 80% were considered for further analysis, which lead to 3,479 transcript clusters. Linear Models for Microarray (LIMMA) (22), a moderated Student’s T-test, was used for detecting differentially expressed genes between groups. Correction for multiple comparisons was performed using false discovery rate (FDR) and only genes with an adjusted $P < 0.05$ were considered significant. Hierarchical cluster analysis was also performed to see how samples and genes aggregated. All data analysis was performed in R (version 2.15.0) with bioconductor (23) and aroma.affymetrix packages (version 2.7.0) (24). Functional analysis was performed using the Ingenuity Pathway Analysis (IPA) (version 8.5) (25) and Gene Set Enrichment Analysis (GSEA) computational method (26). The gene sets with $P < 0.05$ and FDR < 0.2 were considered to be enriched and potentially relevant. The functional heat map was generated by aggregating results of the GSEA and IPA pathway analyses into common categories. The mean of gene expression values belonging to each pathway was taken as the representative value for each sample. Microarray raw data have been deposited in the Gene Expression Omnibus (GEO) database with series accession number GSE45717 (27).

**Gene expression analysis by quantitative RT-PCR (qRT-PCR)**

cDNAs were prepared from 1 µg RNA using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). The following genes were analyzed in an ABI Prism 7900HT instrument (Applied Biosystems): $CCND1$ (Hs00277039_m1), $BTLA$ (Hs00699198_m1), $CD200$ (Hs01033303_m1), $MEF2C$ (Hs00231149_m1), $PON2$
(Hs00165563_m1), **HMGB3** (Hs00801334_m1), **SOX11** (Hs00846583_s1), **CD38** (Hs00233552_m1), **GAB2** (Hs00373045_m1), **LGALS3BP** (Hs00174774_m1), **MYO6** (Hs00192265_m1), **NEO1** (Hs00170143_m1), **TXN** (Hs00828652_m1), **PTK2** (Hs00178587_m1) and **ADAMS28** (Hs00248020_m1) along with beta-glucuronidase (**GUSB**; part number 4326320E) using specific commercially available TaqMan® gene expression assays. Relative expression levels were calculated with the $2^{-\Delta\Delta Ct}$ method using **GUSB** as endogenous control.

**Generation of the CD38/CD200 classifier**

The Classification and Regression Trees strategy (CART) was used to generate a classification algorithm based on CD38 and CD200 expression assessed by flow cytometry. This algorithm was built using R with the rpart package. Rpart is a non-parametrical two-step method, which can be easily represented as a decision tree graph. The first step finds the single variable that best splits the cases into two groups, on the basis of the minimum Gini Index, an estimation based on all possible splits using all available variables. All possible cut-off values for all variables considered in the model are tested to select the split that most decreases the Gini Index at the first node. The cases are then assigned to each newly generated node and this process is recursively applied to each of the descendant nodes, until no improvement can be achieved. In the second step, the resulting full tree is trimmed back using a cross-validation procedure (28). The 95% confidence interval (CI) of the proportions of correctly classified patients by the proposed decision tree were computed using methods with continuity correction (29).

**Statistical Analyses**

Comparisons were performed using the Mann–Whitney's U-test for continuous and ordinal variables and the Fisher's exact test for categorical variables. $P$ values below
0.05 from two-sided tests were considered to indicate statistical significance. The probability of survival was assessed with actuarial life tables, and 95% CI were calculated. The SPSS 16.0 statistical software package (SPSS, Chicago, IL, USA) was used for all statistical analyses.
Results

Clinical presentation, laboratory findings and follow-up of MCL and MALD1 cases

The main clinical and laboratory features at diagnosis are detailed in Table 1 and Supplementary Tables S1 and S2. The reason for referral was different between the two groups: while most MCL patients presented with palpable lymphadenopathies (14/17), 12/13 MALD1 cases were referred because of abnormal routine PB tests, including lymphocytosis (7/13 cases) and atypical lymphocytes in PB smears with a normal lymphocyte count (5/13 cases). In the remaining case, referral was due to a single submandibular lymphadenopathy related to an inflammatory condition (sarcoid granulomatous reaction). In most MALD1 cases, the morphology of abnormal lymphocytes in blood smears was similar to that of typical chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL) without smudge cells, whereas in MCL cases the atypical lymphocytes displayed more irregular nuclear contours, as previously reported (30). The absolute lymphocyte count at presentation ranged from 3.1 to 12.2 x10^9/L in MALD1 cases and from 0.7 to 69 x10^9/L in MCL patients. MALD1 lymphocyte counts over time have been plotted in Supplementary Fig. S1. All MALD1 individuals and most MCL patients (69%) showed PB involvement by flow cytometry, with percentages of abnormal lymphocytes ranging from 11% to 76% in MALD1 cases and from 0% to 86% in MCL patients. There were no significant differences between MALD1 (5/13) and MCL (6/14) cases regarding CD23 expression, nor in the intensity of surface immunoglobulin expression. Interestingly, the moderate/high intensity of surface immunoglobulin expression in all MALD1 cases (13/13) was different to that reported in MBL with typical CLL phenotype, usually negative or weakly positive (31).

MCL cases showed lower hemoglobin level (P = 0.012), with higher erythrocyte sedimentation rates (ESR) and β2-microglobulin levels than MALD1 cases (P = 0.001 for
both variables). Regarding disease stage and both the IPI and MIPI prognostic indexes, no differences were observed between MCL and MALD1 cases. Of note, 69% and 54% of MALD1 cases were assigned to the IPI and MIPI intermediate or high-risk groups, respectively. Overall survival of MCL patients at 2 and 5 years was 88% and 73%, respectively; conversely, all MALD1 individuals remain alive and have not received any treatment with a median follow-up of 71 months (range, 26-186 months).

**MALD1 and MCL show distinct histological features**

The main histological and immunohistochemical features of both groups are detailed in Table 1 and Supplementary Table S1. In MCL patients, the involvement of different organs was apparent in Hematoxylin-Eosin (HE)-stained slides due to the disruption of normal architecture, and it was confirmed by immunohistochemistry (IHC) and FISH techniques. Tissue samples of secondary lymphoid organs were available from 6 MALD1 cases (upper and lower gastrointestinal tract samples in all 6 cases and lymph nodes in two of them). Noteworthy, the presence of the abnormal lymphoid population would not have been suspected by histology alone, in the absence of previous flow cytometry and/or cytogenetic data. The immunohistochemical analysis of secondary lymphoid organs from MALD1 cases identified cyclin D1-positive small lymphoid cells with predominantly round nuclei in 5/6 cases. The cyclin D1-positive cells were mainly located in the lymphoid aggregates lacking germinal centers and in the mantle zones of secondary follicles, without any significant expansion of these areas, thus displaying a so-called *in situ* histological pattern. BM biopsies were available from the aforementioned 6 MALD1 cases. Immunohistochemical analysis revealed the presence of a cyclin D1-positive interstitial lymphoid infiltrate in all of them, which was usually overlooked in HE sections. Only SOX11 and Ki-67 expression were significantly different between MCL and MALD1 groups (*P* < 0.001 and *P* = 0.002, respectively). SOX11 was negative in the
five MALD1 cases in which colonization of secondary lymphoid organs by cyclin D1-positive cells could be proven. On the other hand, 11/11 MCL cases showed strong SOX11 nuclear expression, along with a higher percentage of Ki-67 positive cells.

**MALD1 shares diagnostic cytogenetic and molecular features with MCL**

The main cytogenetic and molecular features are detailed in Table 1 and Supplementary Table S2. All MALD1 and MCL cases displayed a t(11;14)(q13;q32) by G-banding cytogenetics and/or FISH. qRT-PCR analysis confirmed increased CCND1 mRNA expression levels in MALD1 and MCL samples when compared to healthy controls, and these higher levels correlated with cyclin D1 protein overexpression, as detected by IHC. In 0/12 MALD1 and 1/7 MCL cases, the truncated CCND1 mRNA isoform, associated to shorter survival, was identified (19). Analysis of IGH/CCND1 gene rearrangements at the CCND1 MTC breakpoint region showed a similar percentage of events involving this region in MCL and MALD1 cases. There was a difference in size between the PCR product obtained from MALD1 cases (median size of the PCR product: 269 bp; range: 202-288) and that from MCL patients (median size: 212 bp; range: 207-213). However, the structural similarities between MALD1 and MCL breakpoints suggest that the mechanisms leading to the IGH/CCND1 translocation in both groups could not differ in their basis (Supplementary Table S3) (32). Finally, all MALD1 cases analyzed showed clonal IGHVDJ gene rearrangements.

**MALD1 cells are involved in immune reactions and show evidence of transit through the germinal center**

As a part of the routine staging protocol for MCL, upper and lower endoscopy was performed in most cases (33). A follicular chronic gastritis associated with *Helicobacter pylori* infection was detected in gastric mucosa biopsies from three MALD1 subjects.
Immunohistochemical analysis of these samples revealed numerous cyclin D1-positive lymphoid cells in the follicular mantles of the acquired MALT (Fig. 1A, 1B, 1C). FISH analysis confirmed the presence of t(11;14)(q13;q32) in these cells, and molecular analysis showed the same *IGH* clonal rearrangements as those found in the other tissues studied (data not shown). Biopsies taken after routine antibiotic treatment for the gastric infection revealed a slight residual atrophy without evidence of bacilli and, more importantly, complete absence of lymphoid infiltrates (Fig. 1D, 1E, 1F). In contrast, in a MCL patient with concurrent *H. pylori* infection and tumor infiltration, the antibiotic treatment eliminated the *H. pylori* but not the cyclin D1-positive tumor cells.

The above findings suggested that, despite their clonal nature, MALD1 cells could actively participate or be recruited to antigen-driven immune reactions and would disappear from the involved organ when the antigen is cleared. Thus, we next analyzed whether there was any molecular evidence supporting the involvement of MALD1 cells in immune reactions, by assessing the presence of somatic hypermutation events in the *IGHV* genes. Analysis of the mutational status of the *IGHV* genes could be performed in 12/13 MALD1 individuals and in 13/17 MCL patients. All MALD1 cases showed mutated *IGHV* genes, whereas only 4/13 MCL patients had somatic mutations (*P* < 0.001) (Table 1 and Supplementary Table S2). No significant bias in the usage of *VH* segments was observed in any of the two groups. The occurrence of somatic hypermutation events in *IGHV* genes all MALD1 cases indicates that MALD1 lymphocytes may have transited through the germinal center. On the other hand, the percentage of somatic hypermutations in the MCL patients of the present study is 31%, in agreement with previous series (34-36). Remarkably, analysis of the sequences of *VH* segments in sequential samples of three MALD1 individuals showed no evidence of acquired (ongoing) somatic hypermutation events from the time of diagnosis (data not shown). This finding suggests that transit through the germinal center in MALD1 lymphocytes
probably occurred before their clonal expansion, an observation that contrasts with the pre-germinal center origin postulated for MCL (15, 34).

**Gene expression profile of clonal B-cells reveals significant biological differences between MALD1 and MCL**

To better understand the basis for possible biological differences between MCL and MALD1, we analyzed the gene expression profiles of enriched B-cell fractions isolated from PB of five MALD1 subjects, five MCL patients and eight healthy individuals. Unsupervised hierarchical clustering of gene expression data revealed robust differences between MALD1 and MCL B-cells (Fig. 2A). When compared to normal PB B-cells from healthy individuals, MALD1 and MCL clustered together, indicating that PB B-cells from both groups share significant differences with normal B-cells (Fig. 2B). Supervised analysis between MALD1 and MCL samples identified a gene signature composed of 174 differentially expressed transcript clusters (171 genes). This signature clustered together MALD1 and normal B-cells (Fig. 2C, Supplementary Table S4). The microarray results were confirmed by qRT-PCR analysis of a subset of top differentially expressed genes (Supplementary Fig. S2). Validation was performed in the same ten cases (5 MCL and 5 MALD1) used for microarray analyses. The 20 remaining cases (12 MCL and 8 MALD1) were used as a validation set.

The MALD1/MCL gene signature included CD38 (log Fold Change [logFC] =1.51; adj. \( P = 0.024 \)), upregulated in MCL, and CD200 (logFC = 2.04; adj. \( P = 0.005 \)), upregulated in MALD1, two flow cytometry markers commonly used in the study of peripheral blood lymphocytosis. Unlike previous reports (9, 37), SOX11 was not part of the MALD1/MCL gene signature, even though statistically significant differences in SOX11 mRNA expression between MALD1 and MCL were detected by qRT-PCR (Supplementary Fig. S2). This apparent discordance can be explained by the differences
between the probe sets included in the Human Exon 1.0 ST array (used in this study), and the 3'IVT array probe sets (HGU133 Plus2 arrays) used in those studies (Supplementary Fig. S3).

Pathway analysis using the Ingenuity Pathway Analysis tool indicated that the MALD1/MCL gene signature was significantly enriched in genes involved in two main biological processes, namely inflammatory responses in MALD1, and cell growth and proliferation in MCL (Fig. 3, Supplementary Table S5). These differences were confirmed and further refined using the GSEA tool. Many cancer-related signatures (cell cycle and proliferation, Myc deregulation and self-renewal), as well as gene signatures associated to cyclin D1/Cdk4 activation, were specifically enriched in MCL. In addition, we observed a significant enrichment for DNA-damage repair pathways (ATM and global genomic nucleotide excision repair pathways). Both cell cycle and DNA-damage repair related pathways have been previously invoked in the pathogenesis of MCL (28,29). In contrast, MALD1 gene expression profiles were highly enriched in gene sets related to inflammatory responses, B-cell activation, immunoregulatory interactions, cytokine signaling, and lymphocyte/cell adhesion and migration, suggesting that inflammatory cues drive the biology of these cells, as also supported by the histological data (Fig. 1). Thus, gene expression analysis identified significant differences in selected gene expression programs between MCL and MALD1 B-cells, in concordance with the clinical and histological evidence.

**Surface CD38/CD200 expression by flow cytometry is useful to discriminate between MALD1 and MCL**

Among other specific surface molecules found to be differentially expressed between MALD1 and MCL, we chose to further validate CD200 and CD38 on PB samples, given their widespread use in routine phenotypic panels for the study of research.
lymphocytosis (30). Particularly, CD38 was highly expressed in MCL patients but not in MALD1 cases, an observation further confirmed by qRT-PCR analysis ($P = 0.007$) (Fig. 4A). Flow cytometry data on CD38 surface expression in PB were available in 37 cases (11/17 MCL and 13/13 MALD1 from the original series, and 13 additional MCL cases). In agreement with the molecular data, MCL patients displayed a significantly higher percentage of CD38+ B-cells (median 89%, range 0-100%) than that observed among MALD1 individuals (median 14%, range 0-35%) ($P < 0.001$) (Fig. 4B and 4C and Supplementary Table S2).

Regarding CD200, it was highly expressed in MALD1 cases but not in MCL patients, and this observation was confirmed by qRT-PCR ($P < 0.001$) (Fig. 4D). CD200 surface expression was available in PB B-cell lymphocytes of 27 cases (2/17 MCL and 12/13 MALD1 from the original series, and 13 additional MCL cases) (Fig. 4E and 4F, Supplementary Table S2). In agreement with the qRT-PCR data, all MCL cases showed very low or absent CD200 expression (median 0%, range 0-5%), whereas the majority of MALD1 cases analyzed showed a higher percentage of CD200+ B-cells (median 24%, range 0-95%; $P < 0.001$). These observations suggest that flow cytometric analysis of CD38 and CD200 expression on clonal B-cells from PB samples is useful for the distinction between MCL (CD38+/CD200-) and MALD1 cases (CD38-/CD200+). Based on these findings, we designed a classifier to discriminate between both entities in the clinical setting. We generated a CART based on two splits, the first one, CD38 $\geq$ 40%, classifies patients as MCL, whereas the second split, CD200 $\geq$ 2%, assigns the MALD1 cases (Fig. 5A). We have considered a third Non-Classified category, encompassing cases with low values for both markers. This algorithm correctly classified 88% (21/24) (95% CI: [67%; 97%]) of the MCL patients and 85% (11/13) (95% CI: [54%; 97%]) of the MALD1 cases (Fig. 5B and Supplementary Table S6), the rest of the cases remaining as non-classified. Of note, none of the cases was classified in the opposite category. In order
to better characterize the non-classified cases (2 MALD1 and 3 MCL), we analyzed whether SOX11 expression assessed by qRT-PCR could help in classifying these cases. The two MALD1 individuals (MALD1-5 and MALD1-10) displayed low levels of SOX11 expression, as expected. On the other hand, in the 2 MCL cases (MCL-1 and MCL-14) with available sample, SOX11 expression was also low and showed mutated IGHV genes. Interestingly, when analyzing the whole series, mutated IGHV cases showed statistically significant higher levels of SOX11 expression than unmutated cases (P = 0.001). These differences were maintained when considering only MCL patients (P = 0.027).
DISCUSSION

Based on current diagnostic criteria, MCL encompasses a spectrum of cases ranging from the usual, aggressive variants to rare, non-nodal cases that remain asymptomatic for many years, even without treatment (6-13, 38). This clinical heterogeneity probably reflects incomplete knowledge of the MCL pathogenesis, with the resulting diagnostic oversimplification. In fact, current prognostic indexes for MCL (IPI, MIPI) (39, 40) are not suitable for MALD1 cases, as they would label some of them as intermediate or even high-risk MCL, mainly due to the presence of leukocytosis and/or to advanced age, despite their benign clinical course (34). It has been speculated that some of the asymptomatic cases represent a preneoplastic condition that would either lead to the development of MCL or remain stable lifelong (7-13, 15, 41, 42). It is even possible that some asymptomatic cases could belong to a different biological category sharing only some of the diagnostic features of MCL (8, 13, 15). Therefore, it is crucial to gain further insight into the molecular differences between MCL and MALD1 and to find biological markers that, in addition to clinical presentation, allow identifying MALD1 cases and avoid their overtreatment.

While previous series dealing with this topic are rather heterogeneous (7, 9, 10, 12, 13), we have attempted to characterize a homogeneous group of cases (MALD1) presenting without splenomegaly or nodal enlargement due to the disease, and never requiring treatment despite a long follow-up (median, 71 months). This group was compared with a cohort of classical MCL patients, from which aggressive histological variants had been excluded to avoid confounding factors related to disease progression. Despite their clonal nature and the presence of t(11;14)(q13;q32), MALD1 cells lack several common features of MCL B lymphocytes, and are defined by a paucity of genomic abnormalities, a low proliferative fraction, and their recruitment to active inflammatory/immune foci. Moreover, the normal architecture was preserved in all
lymphoid organs analyzed from MALD1 individuals in our series. Characteristically, MALD1 cells have cyclin D1 overexpression and locate only to normal lymphoid structures (i.e., mantle zones), as normal B-cells do in immune reactions. In this regard, we have shown for the first time that in those MALD1 cases with *H. pylori* associated chronic gastritis, cyclin D1-positive cells disappear from the gastric mucosa after antigen elimination by antibiotic therapy (Fig. 1), whereas these cells persist in MCL cases. This different behavior could reflect that presence of MALD1 cells in the gastric mucosa is dependent on the preservation of their homing compartment (acquired MALT). In agreement with these observations, we have also first shown that MALD1 expression profiles are highly enriched in gene sets related to immune activation and inflammatory responses, indicating that inflammatory cues drive the biology of these cells (Fig. 3, Supplementary Table S5). In contrast, gene expression analysis only detected enrichment of signatures associated with neoplastic behavior and proliferation in MCL cases. Consistent with the above observations, MALD1 B lymphocytes showed features of antigen-experienced cells, namely the presence of *IGHV* hypermutations, as well as a replication history (determined by the abundance of IgK-deleting rearrangement excision circles; KREC assay, data not shown) (43), that indicate occasional transit through the germinal center. Notably, the *VH* segment sequences in consecutive samples of three MALD1 individuals showed no evidence of ongoing somatic hypermutation events from the time of diagnosis, strongly suggesting that transit through the germinal center of MALD1 lymphocytes probably occurred before their clonal expansion. These observations contrast with the pre-germinal center origin postulated for most MCL (1).

It is well known that single genetic events are not sufficient for malignant transformation (44, 45). Isolated genetic lesions like t(11;14) should not be used as the only criterion to support the diagnosis of lymphoma. In fact, despite being the primary event in the pathogenesis of MCL, additional oncogenic events are known to be required
for malignant transformation (3, 46). While the biological and clinical behavior of MALD1 is far from that expected in neoplastic cells, we have shown that MALD1 lymphocytes carry genetic abnormalities unseen in normal B-cells as t(11;14), and clonal expansion. This could eventually prime them for neoplastic transformation in the proper biological context. Given the exceptionality and limited knowledge of preneoplastic lesions in the lymphoid system, we cannot rule out that MALD1 may act in the long-term as a precursor of MCL, similar to what has been reported for MBL and CLL (31, 47-49). In this regard, MALD1 cases would be related to the fraction (20-40%) of MCL cases with hypermutated IGHV genes, which typically show non-nodal disease at presentation, an indolent clinical course, and a long disease-free survival (35, 36). Finally, according to our results, another possibility that cannot be excluded is that MALD1 cases might instead belong to a distinct disease category, biologically unrelated to MCL.

Several groups have addressed the need for reliable markers to identify cyclin D1-positive cases not requiring early treatment. Among them, SOX11, for which an oncogenic role has been recently proposed, has been the most widely explored (50, 51). Lack of SOX11 expression, alone or in combination with other genes, has been proposed as a candidate marker with conflicting results (9, 13, 52). The limitation of these markers is that, as the majority of asymptomatic cases only show PB expression, the assessment must be made by qRT-PCR in isolated B-cells from PB. As these techniques are not readily implementable in all laboratories, one of the aims of our study was to identify differentially expressed genes between MALD1 and MCL, providing the basis for a simple routine diagnostic test. Among the differentially expressed and validated genes in our study, we selected CD38 and CD200 because antibodies for their proteins are already used in current diagnostic flow cytometry panels for mature B-cell lymphoproliferative processes (53).
CD38 is an ectoenzyme with an unclear function in B cells (54). CD38 expression is a well-recognized prognostic factor in CLL and it has also been suggested as a marker that partially differentiates nodal from non-nodal MCL (7). In our study, CD38 expression was found to be consistently high in MCL while low or absent in MALD1 cases. It has been proposed that CD38 may favor neoplastic B cell survival by engaging CD31, an adhesion molecule expressed by endothelial cells (55). In MALD1 cases, low CD38 expression may minimize the interaction of MALD1 B cells with CD31-expressing microvessels, thus attenuating clonal B-cell accumulation.

CD200 is an Ig superfamily member frequently upregulated in CLL and has been proposed as a useful marker for the differential diagnosis between CLL and MCL (56, 57). CD200 was found to be consistently low or absent in all MCL, but highly expressed in most MALD1 cases. CD200 binds to CD200R, an inhibitory receptor expressed by both lymphoid and myeloid cells. It is tempting to speculate that an increased frequency of inhibitory signals emerging from CD200-CD200R interaction attenuates the proliferation of MALD1 B cells, thus contributing to the asymptomatic behavior of MALD1 cases. Conversely, reduced CD200 expression by conventional MCL may contribute to its more aggressive biological behavior.

Despite the low prevalence of MALD1 cases, we have generated an algorithm based on CD38 and CD200 expression that correctly assigned most MALD1 and MCL cases; more importantly, such algorithm did not classify any of these cases in the opposite category. SOX11 expression by qRT-PCR did not improve the classification obtained by the algorithm. Our results indicate that a combined analysis of CD38 and CD200 by flow cytometry could be used to discern between MALD1 and MCL. However, as some cases show close values to the cut-off of both markers, these parameters should be considered in the whole clinical and biological context.
In summary, we have studied a very homogeneous group of untreated asymptomatic individuals with monoclonal cyclin D1-positive lymphocytosis and a long follow-up (MALD1). We have shown for the first time that these cases are characterized by immune activation and driven by inflammatory cues. This is in contrast with the biology of overt MCL and translates into a benign clinical behavior. Although more studies with a larger number of cases are needed, our results suggest that combined flow cytometry assessment of CD38 and CD200 expression provides a simple and useful tool to distinguish most MALD1 cases from MCL patients in the clinical setting, which may contribute to avoid overdiagnosis and unnecessary treatment of subjects with MALD1.
Acknowledgments

The authors want to thank Laura Pasqualucci, Katia Basso and Paolo Guarneri (Columbia University, NY, USA), Juan Valcárcel (CRG, Barcelona), Francesc Bosch (Hospital Universitari Vall d'Hebron, Barcelona) and Elías Campo (Hospital Clínic, Barcelona) for valuable comments and insights, and critical reading of the manuscript, Marta Pulido (IMIM, Barcelona) for language assistance, Jesús Mª Hernández-Rivas (Hospital Clínico de Salamanca), Pilar Giraldo (Hospital Miguel Servet, Zaragoza), Nicolás González (Hospital Obispo Polanco, Teruel) and Alicia Smucler (Hospital del Bierzo, Ponferrada) for samples and clinical data, and Teresa Baró, Federico Rojo, Rosa Navarro, Judith González, Carme Melero and María Rodríguez-Rivera (Hospital del Mar, Barcelona) for their expert technical assistance.

Grant Support

This work has been supported in part by grants from Instituto de Salud Carlos III RD07/0020/2004, RD09/0076/00036, RD12/0036/0044, (RTICC, FEDER), Generalitat de Catalunya 2009/SGR541, and the “Xarxa de Bancs de Tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC).
AUTORSHIP

Contribution

B.E., A.F., B.B., L.N., D.D.-S. and S.S. designed and performed research, collected, analyzed, and interpreted data, and drafted and approved the final manuscript; A.S., J.G., M.G.-G., E.L., R.C., J.T.N, E.B., P.A., L.A., C.S., L.F. and F.So. collected, analyzed, and interpreted data and approved the final manuscript; M.C.V., C.F.-R. and E.P. performed research and approved the final manuscript; B.M., A.C., J.L., A.O. and F.Sa. performed research, analyzed, and interpreted data and approved the final manuscript; A.S. and L.N. performed data analysis.

Conflict-of-interest disclosure

The authors declare no competing financial interests.
FIGURE LEGENDS

Figure 1. MALD1 participate in immune reactions. Top panels: Chronic gastritis in a MALD1 case. (A) Lymphoid follicles formation in the lamina propria (HE; × 20); (B) Main image: numerous lymphoid cells overexpressing cyclin D1 in the mantle zone (IHC; × 20); Inset: boundary between the germinal center and mantle zone (IHC; × 700); (C) Abundant *Helicobacter pylori* in the lumen of the gastric pits (Giemsa; × 900). Bottom panels: Post-treatment study of the same case. (D) Mild mucosal atrophy without inflammation (HE; × 40); (E) Absence of lymphoid cells expressing cyclin D1 (IHC; × 40); (F) Absence of *Helicobacter pylori* in the lumen of the gastric pits (Giemsa; × 900).

Figure 2. Gene expression analysis of CD19+ peripheral blood B-cells reveals significant differences between MALD1 and MCL. (A) Unsupervised hierarchical clustering of the gene expression profiles (GEP) from healthy controls (HCTRL), MALD1 and MCL cases. (B) Unsupervised hierarchical clustering of GEP from MALD1 and MCL cases separates the two entities based on distinct gene signatures. (C) Heatmap showing the results of the supervised analysis using genes differentially expressed between MALD1 and MCL cases. The list of genes appearing in the heatmap is detailed, in order of appearance, in Supplementary Table S4.

Figure 3. Biological pathways differentiate MALD1 and MCL cells. Functional heat map showing relative enrichment of biological pathways in the two groups. This heat map was generated by aggregating results of the GSEA and IPA analyses in common categories and taking the mean of gene expression in each pathway as the representative value for each sample.
Figure 4. Differences in CD38 and CD200 surface protein and mRNA expression between MALD1 and MCL cases. (A) Box plots representing the mRNA expression levels of CD38 in the two groups, as determined by qRT-PCR and expressed in relative units (Mann-Whitney test). (B) Box plots depicting the distribution of CD38 positive cells within the clonal peripheral blood B-cell population in the two groups (Mann-Whitney test), as assessed by flow cytometry. (C) Representative examples of flow cytometry analysis of CD38 surface expression in representative MALD1 (top panel) and MCL (bottom panel) peripheral blood B-cells (CD19+, CD5+, highlighted in red on the right panels). The mean fluorescence intensity is used as a parameter to plot the levels of CD38 expression (histograms). (D) Box plot representation of CD200 mRNA total levels in MALD1 and MCL cases and expressed in relative units (Mann-Whitney test). (E) Box plots depicting the distribution of CD200 positive cells within the clonal peripheral blood B-cell population in the two groups (Mann-Whitney test), as assessed by flow cytometry. (F) Representative examples of flow cytometry analysis of CD200 surface expression in representative MALD1 (top panel) and MCL (bottom panel) peripheral blood B-cells (highlighted in red) using the mean fluorescence intensity as a parameter (histograms).

Figure 5. CD38 and CD200 surface expression are helpful to discriminates between MCL and MALD1. (A) Resulting decision tree graph based on CD38 and CD200 expression assessed by flow cytometry classifies cases in three groups: MCL, MALD1 and Non-Classified. (B) Graphical distribution of studied cases depicted in blue (MALD1) and orange (MCL). Blue box corresponds to MALD1 assigned group by the tree, orange box corresponds to MCL assigned group and grey box to the Non-classified group.
### Table 1. Summary of clinical and pathological characteristics, as well as clonal diagnostic markers, of the cases included in the present study

<table>
<thead>
<tr>
<th>Variable</th>
<th>MCL (N=17)</th>
<th>MALD1 (N=13)</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 60 years</td>
<td>11/17 (65)</td>
<td>7/13 (54)</td>
<td>0.711</td>
</tr>
<tr>
<td>Males</td>
<td>7/17 (41)</td>
<td>7/13 (54)</td>
<td>0.713</td>
</tr>
<tr>
<td>B symptoms</td>
<td>4/17 (24)</td>
<td>0/13 (0)</td>
<td>0.113</td>
</tr>
<tr>
<td>Poor performance status (ECOG ≥ 2)</td>
<td>3/17 (18)</td>
<td>0/13 (0)</td>
<td>0.238</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>7/14 (50)</td>
<td>0/13 (0)</td>
<td>0.051</td>
</tr>
<tr>
<td>Hemoglobin level, g/L</td>
<td>117 (67-163)</td>
<td>155 (94-172)</td>
<td>0.012</td>
</tr>
<tr>
<td>Platelet count, x10^{9}/L</td>
<td>183 (50-402)</td>
<td>200 (114-400)</td>
<td>0.391</td>
</tr>
<tr>
<td>Leukocyte count, x10^{9}/L</td>
<td>8.5 (3.8-87)</td>
<td>12.1 (7.0-18.9)</td>
<td>0.286</td>
</tr>
<tr>
<td>Lymphocyte count, x10^{9}/L*</td>
<td>3.6 (0.7-69)</td>
<td>6.5 (3.1-12.2)</td>
<td>0.187</td>
</tr>
<tr>
<td>Albumin &lt; 30 g/L</td>
<td>1/17 (6)</td>
<td>0/13 (0)</td>
<td>1</td>
</tr>
<tr>
<td>ESR mm</td>
<td>39 (7-140)</td>
<td>12 (2-31)</td>
<td>0.001</td>
</tr>
<tr>
<td>LDH level ≥ 450 IU/L</td>
<td>3/17 (19)</td>
<td>1/13 (8)</td>
<td>0.613</td>
</tr>
<tr>
<td>β_2-microglobulin level ≥ 2.1 mg/L</td>
<td>12/17 (70)</td>
<td>1/13 (8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Monoclonal component</td>
<td>3/17 (18) (IgGL, IgMK)</td>
<td>2/13 (15) (IgGL, IgMK)</td>
<td>1</td>
</tr>
<tr>
<td>Advanced stage (Ann Arbor III-IV)</td>
<td>15/17 (88)</td>
<td>13/13 (100)</td>
<td>0.492</td>
</tr>
<tr>
<td>Extranodal involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 1</td>
<td>10/17 (59)</td>
<td>10/13 (77)</td>
<td>0.440</td>
</tr>
<tr>
<td>&gt; 1</td>
<td>7/17 (41)</td>
<td>3/13 (23)</td>
<td></td>
</tr>
<tr>
<td>Bone marrow infiltration (histology and/or cytology)</td>
<td>13/16 (81)</td>
<td>10/10 (100)</td>
<td>0.262</td>
</tr>
<tr>
<td>IPI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>7/17 (41)</td>
<td>4/13 (31)</td>
<td></td>
</tr>
<tr>
<td>Low-intermediate risk</td>
<td>2/17 (12)</td>
<td>8/13 (61)</td>
<td>0.356</td>
</tr>
<tr>
<td>High-intermediate risk</td>
<td>5/17 (29)</td>
<td>1/13 (8)</td>
<td></td>
</tr>
<tr>
<td>High risk</td>
<td>3/17 (18)</td>
<td>0/13 (0)</td>
<td></td>
</tr>
<tr>
<td>MIPI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>10/17 (59)</td>
<td>6/13 (46)</td>
<td></td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>1/17 (6)</td>
<td>6/13 (46)</td>
<td>0.872</td>
</tr>
<tr>
<td>High risk</td>
<td>6/17 (35)</td>
<td>1/13 (8)</td>
<td></td>
</tr>
<tr>
<td>Diffuse pattern in secondary lymphoid organs</td>
<td>7/14 (50)</td>
<td>0/6 (0)</td>
<td>0.106</td>
</tr>
<tr>
<td>Cyclin D1 expression (IHC and/or ICC)</td>
<td>17/17 (100)</td>
<td>13/13 (100)</td>
<td>1</td>
</tr>
<tr>
<td>CD5 expression (IHC and/or FC)</td>
<td>16/16 (100)</td>
<td>10/13 (77)</td>
<td>0.070</td>
</tr>
<tr>
<td>Parameter</td>
<td>Cases/Total Cases (%)</td>
<td>Percentage of Ki-67 positive cells in secondary lymphoid organs (IHC)</td>
<td>t(11;14) alone (CGC)</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-----------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>SOX11 expression (IHC)</td>
<td>11/11 (100)</td>
<td>0/5 (0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>lymphoid organs (IHC)</td>
<td></td>
<td>5 (3-5)</td>
<td></td>
</tr>
<tr>
<td>t(11;14) alone (CGC)</td>
<td></td>
<td></td>
<td>2/8 (25)</td>
</tr>
<tr>
<td>Complex karyotype (CGC)</td>
<td></td>
<td></td>
<td>4/15 (50)</td>
</tr>
<tr>
<td>TP53 deletion (FISH)</td>
<td></td>
<td></td>
<td>3/14 (21)</td>
</tr>
<tr>
<td>ATM deletion (FISH)</td>
<td></td>
<td></td>
<td>4/14 (29)</td>
</tr>
<tr>
<td>MTC rearrangement (PCR)</td>
<td></td>
<td></td>
<td>4/17 (24)</td>
</tr>
<tr>
<td>SOX11 expression (qRT-PCR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGHV hypermutated</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results are expressed as cases/total cases (%) for the categorical variables and median (range) for continuous variables. For further details see Supplementary Tables S1 and S2. MCL, mantle cell lymphoma; MALD1, monoclonal asymptomatic lymphocytosis cyclinD1-positive; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; IPI, international prognostic index; MIPI, MCL international prognostic index; ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry on secondary lymphoid organs and/or BM; ICC, immunocytochemistry on PB; FC, flow cytometry on PB; CGC, conventional G-banding cytogenetics; FISH, fluorescence in situ hybridization; MTC, major translocation cluster; qRT-PCR, quantitative real-time PCR. Parameters showing statistically significant differences between both groups are highlighted in bold. *Normal values for lymphocyte counts in the hospitals submitting cases ranged from 1 to 1.5x10^9/L for minimum values, and from 3 to 5x10^9/L for maximum values.*
References


44. Hirt C, Schuler F, Dolken L, Schmidt CA, Dolken G. Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR. Blood 2004;104:904-5.


Figure 4.

CD38

A

B

P = 0.007

P < 0.001

CD200

D

E

P < 0.001

P < 0.001
Figure 5.

A

Yes

CD38≥40

No

Yes

CD200≥2

No

MCL

MALD1

Non-Classified

B

CD33

MCL

MALD1

CD200

Non-Classified
Clinical Cancer Research

Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry

Blanca Espinet, Ana Ferrer, Beatriz Bellosillo, et al.

Clin Cancer Res Published OnlineFirst December 18, 2013.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-1077

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/12/18/1078-0432.CCR-13-1077.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.